Evan Seigerman, an analyst from BMO Capital, maintained the Hold rating on Bristol-Myers Squibb. The associated price target remains the same with $47.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evan Seigerman has given his Hold rating due to a combination of factors related to Bristol-Myers Squibb’s current market performance and future projections. The launch of Cobenfy, a drug for schizophrenia, has shown a decline in weekly prescriptions, which Seigerman attributes to the shorter holiday week. Despite this, the decline in prescriptions is significant enough to potentially miss the consensus revenue estimates for the third quarter of 2025.
Seigerman’s analysis suggests that while the company’s I/O and hematology businesses are generating stable cash flows, the new product launches, including Cobenfy, are progressing at a slower pace than expected. This slower ramp-up, combined with revised assumptions for gross-to-net discounts and inventory levels, contributes to the Hold rating. The shares are considered fairly valued under these circumstances, leading to a recommendation to maintain current positions rather than increase or decrease holdings.
According to TipRanks, Seigerman is a 3-star analyst with an average return of 3.4% and a 45.28% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Bristol-Myers Squibb, and Eli Lilly & Co.